These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38218536)

  • 1. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
    Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
    Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
    Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
    Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.
    Kaur M; Misra S
    J Basic Clin Physiol Pharmacol; 2024 Nov; 35(6):325-334. PubMed ID: 39385353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
    Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
    Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.
    Heymsfield SB; Coleman LA; Miller R; Rooks DS; Laurent D; Petricoul O; Praestgaard J; Swan T; Wade T; Perry RG; Goodpaster BH; Roubenoff R
    JAMA Netw Open; 2021 Jan; 4(1):e2033457. PubMed ID: 33439265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.
    Garito T; Zakaria M; Papanicolaou DA; Li Y; Pinot P; Petricoul O; Laurent D; Rooks D; Rondon JC; Roubenoff R
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):908-919. PubMed ID: 29566437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of sporadic inclusion body myositis with bimagrumab.
    Amato AA; Sivakumar K; Goyal N; David WS; Salajegheh M; Praestgaard J; Lach-Trifilieff E; Trendelenburg AU; Laurent D; Glass DJ; Roubenoff R; Tseng BS; Greenberg SA
    Neurology; 2014 Dec; 83(24):2239-46. PubMed ID: 25381300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
    Glass DJ
    Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
    Neeland IJ; Linge J; Birkenfeld AL
    Diabetes Obes Metab; 2024 Sep; 26 Suppl 4():16-27. PubMed ID: 38937282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activin type II receptor signaling in cardiac aging and heart failure.
    Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity-related vascular dysfunction persists after weight loss and is associated with decreased vascular glucagon-like peptide receptor in female rats.
    Kiernan R; Persand D; Maddie N; Cai W; Carrillo-Sepulveda MA
    Am J Physiol Heart Circ Physiol; 2022 Aug; 323(2):H301-H311. PubMed ID: 35749717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
    Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
    J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.
    Polkey MI; Praestgaard J; Berwick A; Franssen FME; Singh D; Steiner MC; Casaburi R; Tillmann HC; Lach-Trifilieff E; Roubenoff R; Rooks DS
    Am J Respir Crit Care Med; 2019 Feb; 199(3):313-320. PubMed ID: 30095981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
    He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
    PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.
    Castillero E; Akashi H; Najjar M; Ji R; Brandstetter LM; Wang C; Liao X; Zhang X; Sperry A; Gailes M; Guaman K; Recht A; Schlosberg I; Sweeney HL; Ali ZA; Homma S; Colombo PC; Ferrari G; Schulze PC; George I
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H378-H390. PubMed ID: 31886717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.